On May 21, 2020, Innovation Pharma announced that in vitro research independently conducted at a U.S. Regional Biocontainment Laboratory revealed Brilacidin reduced the viral titer (load) of SARS-CoV-2, the novel coronavirus responsible for COVID-19, by 75 percent, as compared to vehicle control after only 1 hour of preincubation prior to infection. The concentration of Brilacidin tested was 10ﾵM.